You are 28, your BMI reads a comfortable 23, your last fasting sugar came back normal, and a doctor told you there was nothing to look at. For a lot of young Indian adults, that reassurance is the problem. In large Indian datasets, metabolic risk starts climbing from the mid-twenties, often while BMI and fasting glucose still look ordinary. And whether you get screened at all can depend on something that has nothing to do with your body: which country's guideline your doctor happens to follow. This piece sets out what the numbers actually show for the 20 to 35 age band, and what is worth testing.

• In the ICMR-INDIAB national survey, type 2 diabetes prevalence begins rising in the 25-34 age band, earlier than most Western screening rules start looking.
• In a study of lean Asian Indian men at a mean BMI of 24.5 kg/m², 66% were insulin resistant despite normal blood glucose.
• Indian guidance screens all adults from age 30, and earlier for anyone with PCOS, a family history, or a waist above the Indian cut-off. The main US rule starts at 35 and only above BMI 25.
• Waist circumference and the triglyceride-to-HDL ratio describe metabolic risk in young Indians more reliably than BMI alone.
• In India's national PCOS study, 91.9% of women with PCOS had abnormal lipids, often at BMI values a Western chart would call normal.

The clearest Indian signal comes from ICMR-INDIAB, the largest national survey of diabetes and prediabetes across 15 states. In that data, type 2 diabetes prevalence starts rising in the 25-34 age band and keeps climbing into middle age, with urban prevalence running roughly double rural rates. A meaningful share of Indian type 2 diabetes is therefore already present, or building, before the mid-thirties.

What makes this easy to miss is timing. Fasting glucose and HbA1c are lagging indicators: they move once the body's glucose control is already failing. Before that, the changes are quieter. Visceral fat and liver fat accumulate, fasting insulin creeps up, triglycerides rise and HDL falls. A 28-year-old office worker with a BMI of 23 to 24 can be metabolically high-risk while every routine test still reads normal, simply because the tests that would catch it earlier are not the ones usually ordered. That is why "your sugar is fine" reads as a weaker all-clear at 28 than it sounds. It describes today's glucose, not the trajectory underneath it.

The move into a first sedentary job adds to this. A nationally representative Indian study of more than 190,000 adults found that sedentary workers had higher odds of abdominal obesity than active workers, with abdominal obesity affecting roughly 58% of men in sedentary work versus 50% in active work. For a 26-year-old settling into an office chair, waist and lipid markers can drift well before the BMI does.

BMI is a particularly blunt tool for Indian bodies. Studies using CT and DXA scanning consistently find that Asian Indians carry more total and abdominal fat than white Europeans at the same BMI. In one often-cited study of healthy Asian Indian men with a mean BMI of 24.5 kg/m², body fat averaged 33% and 66% of the men were insulin resistant despite normal glucose. Much of that fat is visceral, the metabolically active kind wrapped around the organs rather than sitting under the skin.

The practical consequence is that in the 20 to 35 age band, risk does not track BMI well. Someone can be metabolically unhealthy at a "normal" weight, carrying the visceral fat and insulin resistance that a scale and a BMI chart never register. That thin-outside-fat-inside pattern is one South Asian clinicians describe often, and it is why the Indian waist cut-offs of 90 cm for men and 80 cm for women matter more here than the number on the weighing machine.

A few low-cost markers describe this hidden risk better than BMI alone. None of them diagnoses anything on its own. A clinician reads them together and in context.

Waist circumference: For Indian adults, a waist above 90 cm in men or 80 cm in women meets the Indian abdominal-obesity threshold. It can indicate higher central and visceral fat, even when BMI appears normal.

Triglyceride-to-HDL ratio: Indian studies suggest that a ratio around 3.5 to 4 can be a warning sign. It may indicate insulin resistance and a more atherogenic lipid.

Fasting insulin: An Indian reference study proposed roughly 17 microunits/mL as an upper limit in healthy adults. Higher fasting insulin can indicate hyperinsulinaemia before blood glucose begins to rise.

Fasting insulin and HOMA-IR are research and specialist tools in India, not part of routine national screening. But the underlying point is well supported in Indian data: cross-sectional studies repeatedly find insulin resistance already present in lean young Indian adults.

Here is where the same 28-year-old gets a different answer depending on whose rulebook is open. Indian guidance screens leaner and younger. ICMR's 2018 guidance recommends screening all adults from age 30, and earlier for anyone with a risk factor, a list that explicitly includes a BMI of 23 or above, a large waist, family history, PCOS, acanthosis nigricans, a sedentary lifestyle, or a history of gestational diabetes.

Western guidance is more conservative. The US Preventive Services Task Force recommends screening adults aged 35 to 70, and only those who are overweight or obese by Western cut-offs of BMI 25 or above. The American Diabetes Association is closer to the Indian position once its risk clauses apply: it screens everyone from 35, but also any adult with a BMI of 25 and at least one risk factor, and it names South Asian ethnicity itself as one of those factors.

ICMR 2018 (India): Routine screening starts at age 30, but younger adults may be screened earlier if they have risk factors. A lean young adult can therefore qualify for screening based on factors beyond BMI.
RSSDI-ESI (India): Screening begins at around age 30 with a risk-based approach. The guidance places greater emphasis on identifying metabolic risk earlier in adults who have relevant risk factors.

USPSTF 2021 (US): Screening generally starts at age 35 and applies to adults with a BMI of 25 or above. A lean young adult below this BMI threshold would not typically be screened under this approach.

ADA (US): Screening begins at age 35 for everyone, with screening possible at any age when BMI is 25 or above and at least one additional risk factor is present. A lean young adult would therefore need to meet the applicable BMI and risk criteria.

The gap shows up most sharply in real situations. A 26-year-old woman with a BMI of 23 and PCOS: Indian guidance treats PCOS as a screening trigger and would test her, while the USPSTF rule would not. A 30-year-old man with a BMI of 23 and a wide waist: ICMR considers him due; the USPSTF does not reach him at all. This shows why a young Indian adult and a young American adult with identical numbers can walk out with opposite advice.

For young women, PCOS is often the first metabolic condition to declare itself, and it usually does so in exactly this age band. India's national PCOS study, run by an ICMR-led task force across nearly 9,000 women aged 18 to 40, found prevalence of 7.2% under the strict NIH definition and 19.6% under the broader Rotterdam definition, with a median age of women affected of around 27 to 28.

That near three-fold gap between the two figures is not a contradiction. It is definitional. The NIH criteria require both excess androgens and irregular ovulation, so they miss women with polycystic ovaries and irregular cycles but no obvious androgen excess. The Rotterdam criteria count any two of three features, capturing those "non-classic" phenotypes. Indian practice, especially in specialist centres, has largely moved toward the broader Rotterdam-style definition, precisely because the narrower one under-counts Indian women who still carry real metabolic risk.

The metabolic risk is the point. In the same study, among women with PCOS, 91.9% had abnormal lipids, about a quarter had metabolic syndrome, and roughly a third had fatty liver, much of it at BMIs a Western chart would call normal. A young Indian woman with PCOS warrants a proper metabolic check rather than reassurance based on her weight alone.

None of this calls for panic or self-diagnosis. It calls for measuring the right things at the right time. Drawing on ICMR and RSSDI guidance, a reasonable baseline for an Indian adult aged 20 to 35 with any risk factor, and for most adults by around 30, follows this sequence:

1. Waist circumference and blood pressure: These are the quickest, cheapest signals of central fat and cardiovascular strain.
2. Fasting glucose or HbA1c: The standard starting screen for glucose control, noting that both can appear normal during early insulin resistance.
3. Fasting lipid profile: Lets a clinician read the triglyceride-to-HDL ratio, which describes insulin resistance better than total cholesterol alone.
4. Oral glucose tolerance test: Where PCOS, strong family history or clear central adiposity is in the picture. This catches impaired glucose tolerance that fasting tests can miss in South Asians.
5. Repeat schedule: If everything is normal, every three years is the usual interval, moving to annual checks once any marker is drifting.

Diet and activity changes have the strongest effect when started before glucose control fails. Catching a drift at 28 flags raised risk early enough to act on, well before a standard "your BMI is fine" check would notice anything. And because these markers only carry more weight as risk compounds into your late thirties, acting now buys the most room to change course.

Understanding your numbers is the starting point.

A screening consultation with Voy's clinical team can pull this picture together: waist, blood pressure, glucose and lipids read by a registered clinician, with the decisions that follow made with professional support rather than from a chart or an article.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.